Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics 2010-2015
Case Study - Enabling the Trinity Biotech acquisition of Fiomi Diagnostics
1
The approach Sagentia was asked by Trinity Biotech to conduct the technical due diligence on Fiomi Diagnostics’ cardiac point-of-care diagnostic system prior to its potential acquisition. We evaluated the instrument, consumable and manufacturing processes to comment on robustness; suitability for high volume manufacture; and to identify potential technical hurdles associated with the development of an acceptable product.. The end result Trinity Biotech was better informed about Fiomi Diagnostics and able to make the acquisition for $13.1m with a solid understanding of the company’s current and future Technical due diligence enables acquisition and provides access to $900m market
description
Sagentia was asked by Trinity Biotech to conduct the technical due diligence on Fiomi Diagnostics’ cardiac point-of-care diagnostic system prior to its potential acquisition. http://www.sagentia.com/new-technologies
Transcript of Case Study - Enabling the Trinity Biotech acquisition of Fiomi Diagnostics
![Page 1: Case Study - Enabling the Trinity Biotech acquisition of Fiomi Diagnostics](https://reader037.fdocuments.net/reader037/viewer/2022110302/549689cab47959f07c8b4682/html5/thumbnails/1.jpg)
The approachSagentia was asked by Trinity Biotech to conduct the
technical due diligence on Fiomi Diagnostics’ cardiac point-
of-care diagnostic system prior to its potential acquisition.
We evaluated the instrument, consumable and
manufacturing processes to comment on robustness;
suitability for high volume manufacture; and to identify
potential technical hurdles associated with the
development of an acceptable product..
The end resultTrinity Biotech was better informed about Fiomi Diagnostics
and able to make the acquisition for $13.1m with a solid
understanding of the company’s
current and future
technical position.
Technical due diligence enables acquisition and provides access to $900m market